Portfolio
Kanvas is developing microbiome therapies for various indications including specific cancers and inflammatory bowel disease which affect women mostly and differently.
Reunion Neuroscience’s lead asset is a fast-acting and durable antidepressant for patients suffering from postpartum depression.
IgGenix is developing a monoclonal antibody-based approach to treating peanut allergies. In adults, peanut allergies are more common amongst women versus men.
Gynesonics’ Sonata® System is an incision-free option for treating symptomatic uterine fibroids.
Sequel is developing the next generation of diabetes management solutions. Diabetes has higher morbidity and mortality rates in women.
inSoma Bio’s Fractomer™ technology is an injectable gel that improves breast reconstruction outcomes for women post lumpectomy.
AOA Dx is developing a diagnostic test to detect ovarian cancer at early stages. Their diagnostic test will allow women to seek earlier treatment and improve survival in ovarian cancer patients.
Rejoni is developing a hydrogel product to prevent intrauterine adhesions after uterine surgery.
Nymbl is a digital app that improves balance to prevent falls for older adults. A majority of older adults presenting to ERs for falls are women.
Raydiant Oximetry’s technology is designed to more accurately detect fetal distress during labor and delivery, potentially decreasing the number of medically unnecessary Caesarean sections.
BioAesthetics’ Nipple-Areolar Complex Graft, or NACgraft, is a revolutionary next step in breast reconstruction that will provide patients who have had mastectomies with a new, natural, living nipple and areola.
Trefoil Therapeutics’ novel engineered FGF-1 (eFGF-1) compound helps women (who are the majority of Fuchs’ Dystrophy patients) avoid corneal transplant and relieves associated pain, discomfort, and blurred vision.
Next